428 related articles for article (PubMed ID: 33510832)
1. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both.
Chen Y; Yu M; Huang X; Tu P; Shi P; Maurer M; Zhao Z
World Allergy Organ J; 2021 Jan; 14(1):100501. PubMed ID: 33510832
[TBL] [Abstract][Full Text] [Related]
2. Analysis of the Efficacy and Recurrence of Omalizumab Use in the Treatment of Chronic Spontaneous Urticaria and Chronic Inducible Urticaria.
; Yu R; Qian W; Zheng Q; Xiong J; Chen S; Chen A; Chen J; Fang S; Huang K; Cai T
Int Arch Allergy Immunol; 2023; 184(7):643-655. PubMed ID: 36996780
[TBL] [Abstract][Full Text] [Related]
3. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
Brás R; Esteves Caldeira L; Bernardino A; Costa C
Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
[TBL] [Abstract][Full Text] [Related]
4. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R
J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658
[TBL] [Abstract][Full Text] [Related]
5. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis.
Metz M; Ohanyan T; Church MK; Maurer M
J Dermatol Sci; 2014 Jan; 73(1):57-62. PubMed ID: 24060603
[TBL] [Abstract][Full Text] [Related]
6. Omalizumab on Chronic Spontaneous Urticaria and Chronic Inducible Urticaria: A Real-World Study of Efficacy and Predictors of Treatment Outcome.
Jeong SH; Lim DJ; Chang SE; Kim KH; Kim KJ; Park EJ
J Korean Med Sci; 2022 Jul; 37(27):e211. PubMed ID: 35818702
[TBL] [Abstract][Full Text] [Related]
7. Predicting the Speed of Response to Omalizumab in Chronic Spontaneous Urticaria.
Keskinkaya Z; Kaya Ö; Işık Mermutlu S; Öğretmen Z
Int Arch Allergy Immunol; 2024 Apr; ():1-8. PubMed ID: 38626739
[TBL] [Abstract][Full Text] [Related]
8. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
[No Abstract] [Full Text] [Related]
9. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results.
Maurer M; Giménez-Arnau A; Ensina LF; Chu CY; Jaumont X; Tassinari P
World Allergy Organ J; 2020 Sep; 13(9):100460. PubMed ID: 32983330
[TBL] [Abstract][Full Text] [Related]
10. The autologous serum skin test (ASST) predicts the response to anti-IgE treatment in Chronic Spontaneous Urticaria patients: a prospective study.
Palladino A; Villani F; Pinter E; Visentini M; Asero R
Eur Ann Allergy Clin Immunol; 2024 Mar; ():. PubMed ID: 38482859
[No Abstract] [Full Text] [Related]
11. Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.
Brás R; Costa C; Limão R; Caldeira LE; Paulino M; Pedro E
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2392-2402. PubMed ID: 36720390
[TBL] [Abstract][Full Text] [Related]
12. Comparison between chronic spontaneous urticaria and chronic induced urticaria on the efficacy of omalizumab treatment: A systematic review and meta-analysis.
He ZH; Qiu SC; Huang ZW; Zhang GQ; An QQ; Qu F; Wang N
Dermatol Ther; 2022 Dec; 35(12):e15928. PubMed ID: 36222320
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
14. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers of Autoimmune Chronic Spontaneous Urticaria.
Larenas-Linnemann D
Curr Allergy Asthma Rep; 2023 Dec; 23(12):655-664. PubMed ID: 38064133
[TBL] [Abstract][Full Text] [Related]
16. Treatment and retreatment with omalizumab in chronic spontaneous urticaria: Real life experience with twenty-five patients.
Türk M; Yılmaz İ; Bahçecioğlu SN
Allergol Int; 2018 Jan; 67(1):85-89. PubMed ID: 28566225
[TBL] [Abstract][Full Text] [Related]
17. A comparative analysis of chronic inducible urticaria in 423 patients: Clinical and laboratory features and comorbid conditions.
Ornek Ozdemir S; Kuteyla Can P; Degirmentepe EN; Cure K; Singer R; Kocaturk E
J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):513-520. PubMed ID: 37991240
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab in Chronic Urticaria: An Italian Survey.
Damiani G; Diani M; Conic RRZ; Colli L; Ferrucci S; Martina E; Offidani AM; Pigatto PDM
Int Arch Allergy Immunol; 2019; 178(1):45-49. PubMed ID: 30396176
[TBL] [Abstract][Full Text] [Related]
19. Increased serum free IgE levels in patients with chronic spontaneous urticaria (CSU).
Jang JH; Yang EM; Lee Y; Ye YM; Moon J; Ryu MS; Park HS
World Allergy Organ J; 2022 Feb; 15(2):100629. PubMed ID: 35280503
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors of recurrence after omalizumab cessation in the elderly with urticaria: A real-life study.
Oztop N; Demir S; Unal D; Beyaz S; Terzioglu K; Olgac M; Gelincik A
Allergy Asthma Proc; 2022 Nov; 43(6):519-528. PubMed ID: 36335414
[No Abstract] [Full Text] [Related]
[Next] [New Search]
